This site is intended for Healthcare professionals only.

Lupin receives FDA approval for Clobazam Oral Suspension


Lupin receives FDA approval for Clobazam Oral Suspension

Lupin’s Clobazam Oral Suspension, 2.5 mg/mL is the generic version of Lundbeck Pharmaceuticals, LLC’s Onfi Oral Suspension, 2.5 mg/mL. It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

Mumbai: Pharma major Lupin recently announced that it has received approval for its Clobazam Oral Suspension, 2.5 mg/mL from the United States Food and Drug Administration (FDA) to market a generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, 2.5 mg/mL.

Lupin’s Clobazam Oral Suspension, 2.5 mg/mL is the generic version of Lundbeck Pharmaceuticals, LLC’s Onfi Oral Suspension, 2.5 mg/mL. It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

Clobazam Oral Suspension, 2.5 mg/mL had annual sales of approximately USD 260.2 million in the US.

Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Also Read: Lupin and AbbVie announces partnership to develop, commercialize Novel Oncology Drug



Source: self
0 comment(s) on Lupin receives FDA approval for Clobazam Oral Suspension

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted